The Beginning of the Biosimilars Era in Multiple Sclerosis
Jeff Cohen, MD; Alycin Magruder, PharmD; and Sarah Anderson, PharmD, discuss the recent introduction of biosimilars into the therapeutic landscape of multiple sclerosis, and the downstream effects for physicians, patients, and payers in this new era of treatment.
Resources for Providers and Patients
• Generic and Biosimilar Medications | National MS Society
• Generic and Biosimilar FAQs
• 5 Things to Know About Biosimilars - Momentum Magazine
• Ask an MS Expert: Biosimilars and Generics
• Tyruko News Bulletin
• Patient Assistance Program
• Guide to Prescription Financial Assistance
EP. 2: The Pharmacist Perspective on MS Biosimilars and the Possible Monitoring Needs
October 25th 2023Alicyn Magruder, PharmD, BCACP, MSCS, offers insight into the pharmacist's role in patient education on biosimilars for MS, and the group discusses the potential need for a long-term monitoring system. [WATCH TIME: 10 minutes]
EP. 3: Navigating the Switch From Brand Name to Biosmilar Products With Patients
October 27th 2023Jeff Cohen, MD, and Alicyn Magruder, PharmD, BCACP, MSCS, discuss the best practices when switching to a biosimilar therapy, including patient education and when to consider an insurance appeal. [WATCH TIME: 7 minutes]
EP. 5: Looking Ahead at MS Treatment and Closing Thoughts on Biosimilars
October 31st 2023Jeffrey Cohen, MD; Sarah Anderson, PharmD, NBC-HWC; and Alicyn Magruder, PharmD, BCACP, MSCS, share their final thoughts on the future landscape of clinical MS care in the biosimiliars era. [WATCH TIME: 12 minutes]
